Physician profile
Felixa Supit
NPI 1194214205
$6,906.90
in general payments reported to CMS, 2019-2025
20 companies · $2,879 in 2025
The $2,879 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.50 · 2022: $462 · 2023: $1,695 · 2024: $1,779 · 2025: $2,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,353.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,522.55 | 2021-2025 | Descovy, Yeztugo, Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,233.31 | 2022-2025 | Caplyta |
| Viiv Healthcare Company | $1,099.42 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Otsuka America Pharmaceutical, INC. | $659.05 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $494.58 | 2022-2025 | |
| Lilly USA, LLC | $400.99 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Vanda Pharmaceuticals INC. | $349.19 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $308.42 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $158.42 | 2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $120.54 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $113.12 | 2023 | Austedo Xr |
| Abiomed | $105.61 | 2023 | Impella |
| Janssen Products, LP | $100.15 | 2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $68.69 | 2024 | Farxiga |
| Janssen Biotech, INC. | $43.21 | 2023 | Symtuza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39.27 | 2024 | |
| Phathom Pharmaceuticals, INC. | $35.55 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $23.32 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $17.09 | 2024 | Ingrezza |
| Shield Therapeutics INC | $14.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felixa Supit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.